MDR- and CYP3A4-Mediated Drug–Drug Interactions

[H Bomber]

File Archive
A new entry has been added to Pharmacology

Description:
P-glycoprotein (P-gp), multiple drug resistance
associated proteins (MRPs), and cytochrome P450 3A4 together constitute a highly efficient barrier for many orally absorbed drugs. Multidrug regimens and corresponding drug–drug interactions are known to cause many adverse drug reactions and treatment failures. Available literature, clinical reports, and in vitro studies from our laboratory
indicate that many drugs are substrates for both P-gp and CYP3A4. Our primary hypothesis is that transport and metabolism of protease inhibitors (PIs) and NNRTIs will be altered when administered in combination with azole antifungals, macrolide, fluroquinolone antibiotics, statins, cardiovascular agents, immune modulators, and recreational
drugs [benzodiazepines, cocaine, lysergic acid dithylamide (LSD), marijuana, amphetamine (Meth), 3,4-methylenedioxymethamphetamine (MDMA), and opiates] due to efflux, and/or metabolism at cellular targets. Therefore, such drug combinations could be a reason for the unexpected and unexplainable therapeutic outcomes. A number of clinical reports on drug interaction between PIs and other classes (macrolide antibiotics, azole antifungals, cholesterol lowering statins, cardiovascular medicines, and
immunomodulators) are discussed in this article.

To check it out, rate it or add comments, visit MDR- and CYP3A4-Mediated Drug–Drug Interactions
The comments you make there will appear in the posts below.

[H Bomber]

Comment:

Quite comprehensive

To check this out, and rate it or add your own comments, visit MDR- and CYP3A4-Mediated Drug–Drug Interactions.
The comments you make there will appear in the posts below.